Ingrid Yin

In a report published Tuesday, Oppenheimer analyst Ingrid Yin upgraded the rating on Mead Johnson Nutrition Co. (NYSE: MJN) from Perform to Outperform, and named a $100.00 price target. In the report, Oppenheimer noted, “Recently China announced further loosening of the ‘One-Child Policy,'...

In a report published Wednesday, Oppenheimer analyst Ingrid Yin upgraded the rating on Synutra International (NASDAQ: SYUT) from Perform to Outperform, and named a $10.00 price target. In the report, Oppenheimer noted, “SYUT reported 2Q14 revenue of $88.6M, beating OPCO estimate of $80.6M,...

In a report published Tuesday, Oppenheimer analyst Ingrid Yin reiterated an Outperform rating on WuXi PharmaTech (NYSE: WX), and raised the price target from $25.00 to $28.00. In the report, Oppenheimer noted, “WX's performance beat expectations again in 2Q13. Revenue beat OPCO/consensus...

Brean, Murray, Carret & Co. analyst Ingrid Yin maintained her Buy rating for shares of China Biologic Products, Inc. (Nasdaq: CBPO) and raised the price target to $20 per share, from the previous price target of $19. The analysts said that China Biologic Products, Inc. had announced that the...